Lumi Research

Running trials

• Recruiting

  Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

  NCT07718737· Phase 2/3· Source

• Recruiting

  Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  NCT06899126· Phase 3· Source

• Recruiting

  Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

  NCT06937177· Phase 2· Source

• Active, not recruiting

  To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

  NCT05468489· Phase 3· Source

• Recruiting

  A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  NCT05254743· Phase 3· Source

• Active, not recruiting

  CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

  NCT05306288· Source

• Active, not recruiting

  A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

  NCT05094336· Phase 1/2· Source

• Active, not recruiting

  GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

  NCT04083599· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Pancreatic cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  NCT05894239· Phase 3· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

  NCT05646862· Phase 3· Source

• Completed

  Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

  NCT05198934· Phase 3· Source

• Completed

  Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

  NCT05103358· Phase 2· Source

• Recruiting

  A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

  NCT04929223· Phase 1· Source